|
Post by novafett on Apr 27, 2015 10:53:58 GMT -5
Haven't followed what's going on w/ MNKD of late. (Took a different job at work and have been swamped for a few months). I recently had some breathing room and checked to see to my surprise that MNKD is 3.17% lower than my cost basis.
I have to say i'm a bit shocked and surprised to see it down here. Anyone able to provide a quick summary of what has transpired over the last couple of months to drive it down so much?
|
|
|
Post by nadathing on Apr 27, 2015 10:57:35 GMT -5
I'm in the red now too. I was hoping last year to cash in a few thousand shares and buy a boat. I was sure this would be the year. I can always dream that maybe it will be next year, but what a huge disappointment this is.
|
|
|
Post by babaoriley on Apr 27, 2015 12:21:49 GMT -5
nada, go ahead and buy the boat, I'll send you the two D-cell batteries to run it!
|
|
|
Post by spiro on Apr 27, 2015 12:49:05 GMT -5
Baba, can you send Spiro a couple of D-cells also for his new car?
|
|
|
Post by benh on Apr 27, 2015 12:49:21 GMT -5
Anyone that has bought in the last year is in the red. Unless they were that genius that bought in the 2nd hour of trading on Oct 13th 2014. Since the 14th May 2013, there have been just 6 days that you could have got in lower. And even then you would have needed to shoot from the hip to stand a chance. As far as catalyst go, there's a lot riding on Oxyntomodulin presentation tomorrow.
|
|
|
Post by harshal1981 on Apr 27, 2015 12:54:05 GMT -5
Anyone that has bought in the last year is in the red. Unless they were that genius that bought in the 2nd hour of trading on Oct 13th 2014. Since the 14th May 2013, there have been just 6 days that you could have got in lower. And even then you would have needed to shoot from the hip to stand a chance. As far as catalyst go, there's a lot riding on Oxyntomodulin presentation tomorrow. What presentation you are talking about?
|
|
|
Post by otherottawaguy on Apr 27, 2015 13:20:50 GMT -5
www.gtcbio.com/conferences/diabetes-drug-discovery-development-agendaFEATURED SPEAKER 11:00 Dry Powder Formulations for the Inhalation of Oxyntomodulin Andrea Leone-Bay Vice President Scientific Research Mannkind Obesity is a rapidly becoming a global epidemic and underlies many disease conditions including diabetes and cardiovascular disease. Current treatment options are limited and are challenged by undesirable side effects. Oxyntomodulin (OXY) is an endogenous peptide hormone that signals satiety in healthy individuals. High circulating OXY concentrations are associated with satiety and low OXY concentrations are associated with a feeling of hunger. This activity profile positions OXY as a potential treatment for obesity. To address this unmet medical need, this presentation will introduce an approach to developing an orally inhaled dry powder OXY product administered using a small, breath-powered inhaler for obesity therapy. The audience will learn about oxyntomodulin, a potential new obesity therapy and about the administration of peptides by oral inhalation using a simple, patient-friendly approach
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 27, 2015 13:32:13 GMT -5
Anyone that has bought in the last year is in the red. Unless they were that genius that bought in the 2nd hour of trading on Oct 13th 2014. Since the 14th May 2013, there have been just 6 days that you could have got in lower. And even then you would have needed to shoot from the hip to stand a chance. As far as catalyst go, there's a lot riding on Oxyntomodulin presentation tomorrow. nothing new in that presentation.. Oxyntomodulin has been known before..I dont think that will move the share price
|
|
|
Post by dreamboatcruise on Apr 27, 2015 13:32:20 GMT -5
Haven't followed what's going on w/ MNKD of late. (Took a different job at work and have been swamped for a few months). I recently had some breathing room and checked to see to my surprise that MNKD is 3.17% lower than my cost basis. I have to say i'm a bit shocked and surprised to see it down here. Anyone able to provide a quick summary of what has transpired over the last couple of months to drive it down so much? Script number are quite low representing a very slow launch. Shorts imply this is indicative that Afrezza is nothing more than exubera and doomed to its fate. Weaker longs are likely giving up. Doesn't help on days like today when biotech is being pounded in general. To me the past couple of months seems to be showing that Sanofi really does have a phased launch strategy and that the number of doctors who have been targeted to date is likely quite low. Hopefully this is an intelligent strategy based on initially developing key industry advocates and on the problem of "access" (negotiating with PBM and insurers to adequately cover Afrezza). I personally am hopeful that we'll get a step change in activity at the upcoming June ADA conference. That's my summary of last few months... for what it's worth. I too am now underwater... after doing some averaging up over the past year. I did nibble on some more shares today.
|
|
|
Post by gomnkd on Apr 27, 2015 13:35:38 GMT -5
I'm in the red now too. I was hoping last year to cash in a few thousand shares and buy a boat. I was sure this would be the year. I can always dream that maybe it will be next year, but what a huge disappointment this is. Looking at your profile picture, you need to first buy a trouser. If you delay longer, your few tho shares will only buy you a short.
|
|
|
Post by benh on Apr 27, 2015 14:07:04 GMT -5
iam2sekc4u2002 - Quote isn't working for me.
Whilst my sensible side agrees with you. The not so sensible side has lit the hopium pipe, looking for a snippet of price-stabilizing info
|
|
|
Post by novafett on Apr 28, 2015 10:28:58 GMT -5
Thanks all for the info. Here's to hoping we are in the black this time next year or sooner even!
|
|
|
Post by afrizzle on Apr 28, 2015 19:15:23 GMT -5
Also, there is a strong indication of naked shorting, there are around 100 million shares short and the failure to deliver rate is high
Any time a rally starts or momentum turns positive. A surrogate or writer for "the street" launches a hit piece. If that doesn't do it, Goldman Sachs lowers their target price, while (many suspect) they are quietly accumulating in the background either directly or by tipping friends.
|
|
|
Post by Chris-C on Apr 28, 2015 20:06:03 GMT -5
Thanks all for the info. Here's to hoping we are in the black this time next year or sooner even! Nova- Wait! You mean (beyond Dreamboat's reply) there was a sufficient answer to your question in this thread? You are either extremely kind or clairvoyant! Or your question was rhetorical. I have a slightly different take. What happened was manipulation by hedgies shorting the stock with Goldman-Sachs issuing a questionable (if not unscrupulous) downgrade. Otherwise the news was positive except that sales were "contained" and failed to meet the street's unrealistic expectations - thus giving additional ammo to the FUDsters.When GS issued it's downgrade, however, it was simply ridiculous to claim script numbers as the reason for the downgrade. Only an incompetent analyst (or one with an agenda) could possibly have done a realistic projection of sales at that point. Until it's clear what the game plan is with SNY, I don't even think the first 12 weeks is sufficient to predict adoption 12 months from now. So, don't give up and buy the plastic boat quite yet- I'm confident things will be quite different 12 months from now, and I agree with Dream that ADA (and possible the annual shareholder's meeting) may change things a bit. I'm reasonably sure that the significant short attack over the past week was not random timing. GLTAL Chris
|
|
|
Post by jpg on Apr 28, 2015 20:50:55 GMT -5
Do notice some of the usual suspects are absent from this board when the price action is neutral or up...
Hmmm.
|
|